Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Glaukos Corp (GKOS)

Glaukos Corp (GKOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,251,800
  • Shares Outstanding, K 57,435
  • Annual Sales, $ 383,480 K
  • Annual Income, $ -146,370 K
  • EBIT $ -88 M
  • EBITDA $ -52 M
  • 60-Month Beta 0.69
  • Price/Sales 16.09
  • Price/Cash Flow N/A
  • Price/Book 8.02

Options Overview Details

View History
  • Implied Volatility 52.99% (+5.07%)
  • Historical Volatility 51.05%
  • IV Percentile 49%
  • IV Rank 34.23%
  • IV High 92.88% on 04/11/25
  • IV Low 32.23% on 12/12/24
  • Expected Move (DTE 14) 7.06 (6.50%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 54
  • Volume Avg (30-Day) 318
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 2,859
  • Open Int (30-Day) 6,786
  • Expected Range 101.46 to 115.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.22
  • Number of Estimates 7
  • High Estimate -0.09
  • Low Estimate -0.30
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +45.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.90 +34.12%
on 11/07/25
112.00 -3.12%
on 12/05/25
+24.16 (+28.64%)
since 11/05/25
3-Month
73.16 +48.32%
on 10/28/25
112.00 -3.12%
on 12/05/25
+14.57 (+15.51%)
since 09/05/25
52-Week
73.16 +48.32%
on 10/28/25
163.71 -33.72%
on 01/23/25
-27.19 (-20.04%)
since 12/05/24

Most Recent Stories

More News
Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 108.51 (-0.31%)
Glaukos: Q3 Earnings Snapshot

Glaukos: Q3 Earnings Snapshot

GKOS : 108.51 (-0.31%)
Glaukos Announces Third Quarter 2025 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 108.51 (-0.31%)
Glaukos Announces FDA Approval of Epioxaâ„¢

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel,...

GKOS : 108.51 (-0.31%)
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced...

GKOS : 108.51 (-0.31%)
Stifel Nicolaus Remains a Buy on Glaukos (GKOS)

Stifel Nicolaus analyst Thomas Stephan reiterated a Buy rating on Glaukos today and set a price target of $115.00. The company’s shares opened today at $86.40.Elevate Your Investing Strategy: Take advantage...

GKOS : 108.51 (-0.31%)
Glaukos (GKOS) Gets a Buy from Citi

In a report released on October 3, Joanne Wuensch from Citi maintained a Buy rating on Glaukos, with a price target of $110.00. The company’s shares closed yesterday at $86.62.Elevate Your Investing...

GKOS : 108.51 (-0.31%)
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Conference Call and Webcast Scheduled for 1:30 p.m. PT

GKOS : 108.51 (-0.31%)
Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Planned Investment of $80+ Million in 200,000 Square-Foot State-of-the-Art Facility Supports Glaukos’ Long-Term Growth Plans and Reinforces Commitment to U.S. Manufacturing

GKOS : 108.51 (-0.31%)
Glaukos Announces Participation in Wells Fargo Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 108.51 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an...

See More

Key Turning Points

3rd Resistance Point 115.47
2nd Resistance Point 113.74
1st Resistance Point 111.12
Last Price 108.51
1st Support Level 106.77
2nd Support Level 105.04
3rd Support Level 102.42

See More

52-Week High 163.71
Fibonacci 61.8% 129.12
Fibonacci 50% 118.44
Last Price 108.51
Fibonacci 38.2% 107.75
52-Week Low 73.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar